Bradyzide di(trifluoroacetate) salt hydrate, >=98%

Biochem/physiol Actions

Potent, orally active, non-peptide B2 bradykinin receptor antagonist.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5 mg in glass bottle

25 mg in poly bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3589700 Bradyzide di(trifluoroacetate) salt hydrate, >=98% 100 SIGMA-ALDRICH −20°C H2O: >40 mg/mL solid ≥98%
Click Add to Quote for price and delivery
-
+
3589701 Bradyzide di(trifluoroacetate) salt hydrate, >=98% 100 SIGMA-ALDRICH −20°C H2O: >40 mg/mL solid ≥98%
Click Add to Quote for price and delivery
-
+